441 results on '"Polak, Sebastian"'
Search Results
52. Prediction of the hERG potassium channel inhibition potential with use of artificial neural networks
53. An open-access data set of pig skin anatomy and physiology for modelling purposes
54. Model of the Distribution of Diastolic Left Ventricular Posterior Wall Thickness in Healthy Adults and Its Impact on the Behavior of a String of Virtual Cardiomyocytes
55. Plasma vs heart tissue concentration in humans – literature data analysis of drugs distribution
56. Development of physiologically based pharmacokinetic model for the immediate release ropinirole tablets
57. Inter-individual Variability in the Pre-clinical Drug Cardiotoxic Safety Assessment—Analysis of the Age–Cardiomyocytes Electric Capacitance Dependence
58. Artificial neural networks based Internet hypertension prediction tool development and validation
59. Artificial neural networks based modeling for pharmacoeconomics application
60. Analysis of non-hospital antibacterial pharmacotherapy in Poland
61. Utilization of mechanistic modelling and simulation to analyze fenspiride proarrhythmic potency–role of physiological and other non-drug related parameters
62. The database for in silico cardiac risk prediction tools
63. Combining an in silico pro-arrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig
64. Assessment of inter-individual variability in predicted phenytoin clearance
65. Computer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challenges
66. Population-Based Mechanistic Prediction of Oral Drug Absorption
67. Magnetic Core–Shell Molecularly Imprinted Nano-Conjugates for Extraction of Antazoline and Hydroxyantazoline from Human Plasma—Material Characterization, Theoretical Analysis and Pharmacokinetics
68. Characterization of In Vitro and In Vivo Metabolism of Antazoline Using Liquid Chromatography-Tandem Mass Spectrometry
69. BDTcomparator: a program for comparing binary classifiers
70. Evolutionary Algorithms in Modeling Aerodynamic Properties of Spray-Dried Microparticulate Systems
71. Physiologically Based Pharmacokinetic Modeling of Transdermal Selegiline and Its Metabolites for the Evaluation of Disposition Differences between Healthy and Special Populations
72. Drug Therapy Optimization System Based on a Hybrid Approach Combining Clinical Data and In Silico Modeling - Perspective View and Concept Description
73. Combining an in silico proarrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig assay
74. An Open-Access Dataset of Thorough QT Studies Results
75. MODELLING AND SIMULATION IN MODERN PHARMACY -BRIDGING REGULATORY BODIES, ACADEMIA AND INDUSTRY: O07
76. open-access data set of pig skin anatomy and physiology for modelling purposes.
77. Optimizing drug discovery by Investigative Toxicology: Current and future trends
78. Artificial intelligence technology as a tool for initial GDM screening
79. Optimizing drug discovery by Investigative Toxicology: Current and future trends
80. Optimizing drug discovery by Investigative Toxicology: Current and future trends
81. Drug interaction at hERG channel : in vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models
82. Physiologically based pharmacokinetic modelling to guide drug delivery in older people
83. Effect of multiple drugs interacting with the hERG channel—In vitro study
84. Utilizing postmortem drug concentrations in mechanistic modeling and simulation of cardiac effects: a proof of concept study with methadone
85. In Vitro-In Vivo Correlation (IVIVC): From Current Achievements Towards the Future
86. Quantitative Assessment of the Physiological Parameters Influencing QT Interval Response to Medication: Application of Computational Intelligence Tools
87. Combining systems biology and pharmacokinetics - drug cardiotoxicity assessment
88. Techniczne aspekty praktyki farmaceutycznej
89. Additional file 1: Table S1. of Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials
90. Virtual patient case studies in pharmacy education - how to make it work and worth
91. Drug interaction at hERG channel: In vitro assessment of the electrophysiological consequences of drug combinations and comparison against theoretical models
92. Quantitative Assessment of the Physiological Parameters Influencing QT Interval Response to Medication - Simulation Study
93. Various Mathematical Models Towards Assessment of the Cardiac Consequences of Drug Combinations and Multiple-currents Inhibition: In Silico Study to Predict In Vivo Effects
94. Comparison of Proarrhythymia Classification Models
95. Humans Vary, So Cardiac Models Should Account for That Too!
96. In Silico Assessment of Nifedipine Effects on Human Heart Cells: Pharmacokinetic-Pharmacodynamic Analyses at the Population Level
97. A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application
98. From in vitro-in vivo relationship (IVIVR) towards in vitro-in vivo extrapolation (IVIVE): A case study of pulmonary delivery systems
99. Comment on “In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically-Based Absorption Models”
100. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.